Cisco on Deck: What...
Health Care: Drugs
Alnylam Pharmaceuticals Inc. (ALNY: NASDAQ)
$13.05 0.10 | 0.77%
02/08/12 - 04:00 PM ET
569.48K / 307.30K
Vol / Avg. Vol:13.02 / 12.95
Open / Prev. Close:12.65 - 13.15
Today's Range:5.88 - 13.25
52 Wk Range:60.12%
Performance YTD:TheStreet Rating:
Portfolios with ALNY
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- Userkite
- UserPART 6 JPMorgan 28th Annual...
- UserWilliam T Blanchard - Medical
- ContributorHealthcare Short Squeezes f...
- UserS.A.Chili
- UserHancock Hallock Firm
- UserCramer's Take on Top Search...
- UserPART 5 JPMorgan 27th Annual...
- Usermarshall putterman Portfolio 1
Latest ALNY Headlines from TheStreet
- 'Mad Money Lightning Round': Stay Long Sandridge 01.03.12 | 07:01 pm
- Cramer's 'Mad Money' Recap: Betting Against the Bears (Update 2) 01.03.12 | 06:01 pm
- AK Steel, Applied Materials: New Ratings 02.23.11 | 09:02 am
- Layoffs Mount in 2010: What Does It Mean for 2011? 01.06.11 | 05:01 pm
- Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results  Earnings Call Transcript 11.03.10 | 10:11 pm
- Biotech Stock Mailbag: Cyclacel Pharma 10.08.10 | 07:10 am
- Alnylam Cuts Jobs On Partner Exit 09.24.10 | 07:09 am
- Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript 08.05.10 | 12:08 am
- Alnylam Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript 05.05.10 | 10:05 pm
- 7 Firms Developing RNAi Drugs 03.30.10 | 06:03 am
Press Releases for ALNY
- Alnylam To Webcast Conference Call Discussing Fourth Quarter And 2011 Financial Results - Business Wire 02.02.12 | 04:02 pm
- Alnylam Receives Notice Of Allowance From United States Patent And Trademark Office (USPTO) For New Patent Broadly Covering Second Generation Lipid Nanoparticles (LNP) For Systemic Delivery Of RNAi Therapeutics - Business Wire 01.30.12 | 08:01 am
- Alnylam To Restructure Organization, Aligning Resources With Focus On Highest Value Pipeline Opportunities In “Alnylam 5x15™” Product Strategy - Business Wire 01.19.12 | 06:01 pm
- Alnylam Files Patent Infringement Suit Against Tekmira - Business Wire 01.17.12 | 09:01 am
- Alnylam Provides Key 2012 Goals For RNAi Therapeutics Pipeline - Business Wire 01.08.12 | 04:01 pm
- Alnylam Files Clinical Trial Application For ALN-TTR02, An RNAi Therapeutic Targeting Transthyretin For The Treatment Of Transthyretin-Mediated Amyloidosis - Business Wire 01.06.12 | 08:01 am
- Regulus Therapeutics To Present MicroRNA Platform And Pipeline Updates At Two Leading Scientific Conferences - PR Newswire 01.05.12 | 08:01 am
- Alnylam And Arrowhead Form Collaboration And Licensing Agreement - Business Wire 01.05.12 | 08:01 am
- Alnylam To Webcast Presentation At 30th Annual J.P. Morgan Healthcare Conference 2012 - Business Wire 01.04.12 | 04:01 pm
- Alnylam Reports Positive Preliminary Clinical Results For ALN-PCS, An RNAi Therapeutic Targeting PCSK9 For The Treatment Of Severe Hypercholesterolemia - Business Wire 01.04.12 | 06:01 am
Partner Headlines for ALNY
- Verastem IPO Validates Investor Interest In Cancer Stem Cell Approach - Seeking Alpha 01.30.12 | 09:01 am
- Alnylam Down to Neutral - Analyst Blog - Zacks 01.20.12 | 04:01 pm
- 16 Healthcare Stocks Deeply Discounted From Target Price - Seeking Alpha 01.12.12 | 09:01 am
- Alnylam States Preclinical Data - Analyst Blog - Zacks 12.30.11 | 04:12 pm
- Wider Loss at Isis Pharma - Analyst Blog - Zacks 11.10.11 | 10:11 am
- Rodman & Renshaw Maintains Market Outperform Rating and $12 PT on Alnylam Pharmaceuticals - Benzinga 11.01.11 | 09:11 am
- Zacks #1 Rank Additions for Monday - Tale of the Tape - Zacks 10.31.11 | 09:10 am
- 3 Biotech Takeover/LBO Targets With Bullish Short Trends - Seeking Alpha 10.26.11 | 09:10 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 10.25.11 | 09:10 am
- Zacks #1 Rank Additions for Wednesday - Tale of the Tape - Zacks 10.19.11 | 09:10 am
